Treatment and prevention of cytomegalovirus infection in heart and lung transplantation: an update

Expert Opinion on Pharmacotherapy

Volumn 17, Issue 12, 2016, Pages 1611-1622

  Potena, Luciano ^a   Solidoro, Paolo ^b   Patrucco, Filippo ^b   Borgese, Laura ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b CITTÀ DELLA SALUTE E DELLA SCIENZA HOSPITAL   (Italy)

Author keywords

Cytomegalovirus; ganciclovir; heart transplant; lung transplant; prevention; therapy

Indexed keywords

ACICLOVIR; ACICLOVIR TRIPHOSPHATE; BRINCIDOFOVIR; CIDOFOVIR; CYTOMEGALOVIRUS ANTIBODY; FOSCARNET; GANCICLOVIR; VALGANCICLOVIR; ANTIVIRUS AGENT; IMMUNOSUPPRESSIVE AGENT; VIRUS ANTIBODY;

ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; HEART TRANSPLANTATION; HUMAN; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION PREVENTION; LUNG TRANSPLANTATION; META ANALYSIS (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW (TOPIC); ADVERSE EFFECTS; BLOOD; CYTOMEGALOVIRUS INFECTIONS; GENETICS; GRAFT REJECTION; IMMUNOLOGY; ISOLATION AND PURIFICATION;

ANTIBODIES, VIRAL; ANTIVIRAL AGENTS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DRUG RESISTANCE, VIRAL; GANCICLOVIR; GRAFT REJECTION; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUNG TRANSPLANTATION;

EID: 84979300132     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1080/14656566.2016.1199684     Document Type: Review

References (119)

1. L.Potena, C.T.Holweg, M.L.Vana, et al. Frequent occult infection with Cytomegalovirus in cardiac transplant recipients despite antiviral prophylaxis. J Clin Microbiol. 2007;45:1804–1810.
2. C.N.Kotton, D.Kumar, A.M.Caliendo, et al. Updated international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. Transplantation. 2013;96:333–360.• This document represents an important reference point for CMV management and its supportive evidences.
3. N.S.Cytomegalovirus Textbook of human virology. St. Louis, MO: Mosby-Year Book Inc; 1991. p. 889–924.
4. E.S.MocarskiJr. Immunomodulation by cytomegaloviruses: manipulative strategies beyond evasion. Trends Microbiol. 2002;10:332–339.
5. S.B.Kudchodkar, Y.Yu, T.G.Maguire, et al. Human cytomegalovirus infection induces rapamycin-insensitive phosphorylation of downstream effectors of mTOR kinase. J Virol. 2004;78:11030–11039.
6. Rowshani AT, Bemelman FJ, van Leeuwen EM, van Lier RA, ten Berge IJ. Clinical and immunologic aspects of cytomegalovirus infection in solid organ transplant recipients. Transplantation. 2005;79:381–386.
7. L.D.Thomas, A.P.Milstone, G.G.Miller, et al. Long-term outcomes of cytomegalovirus infection and disease after lung or heart-lung transplantation with a delayed ganciclovir regimen. Clin Transplant. 2009;23:476–483.
8. L.Potena, H.A.Valantine. Cytomegalovirus-associated allograft rejection in heart transplant patients. Curr Opin Infect Dis. 2007;20:425–431.
9. P.Solidoro, E.Balestro, M.Boffini. Viral infections in lung transplant recipients: devils or trolls? Minerva Med. 2014;105(Suppl 2–3):15–21.
10. D.Kumar, A.Humar. Respiratory viral infections in transplant and oncology patients. Infect Dis Clin North Am. 2010;24:395–412.
11. D.R.Snydman, A.P.Limaye, L.Potena, et al. Update and review: state-of-the-art management of cytomegalovirus infection and disease following thoracic organ transplantation. Transplant Proc. 2011;43:S1–S17.
12. E.J.Prisbe, J.C.Martin, D.P.McGee, et al. Synthesis and antiherpes virus activity of phosphate and phosphonate derivatives of 9-[(1,3-dihydroxy-2-propoxy)methyl]guanine. J Med Chem. 1986;29:671–675.
13. A.P.Limaye. Ganciclovir-resistant cytomegalovirus in organ transplant recipients. Clin Infect Dis. 2002;35:866–872.
14. N.S.Lurain, S.Chou. Antiviral drug resistance of human cytomegalovirus. Clin Microbiol Rev. 2010;23:689–712.
15. O.Ds, A.C.Webster, G.F.Strippoli, et al. Pre-emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ transplant recipients. Cochrane Database Syst Rev. 2013;2:CD005133.•• A very extensive and comprehensive systematic review dissecting the evidences supporting preemptive anti-CMV strategies in solid organ transplantation.
16. H.Em, M.Ladhani, A.C.Webster, et al. Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients. Cochrane Database Syst Rev. 2013;2:CD003774.•• This important paper is a companion to the one referenced at [15]. Here, the Cochrane group performs a complex and extensive meta-analysis of studies on CMV prophylaxis versus placebo or comparing different prophylaxis regiments. It is one of the few available papers providing evidences in the comparison among different antiviral treatments.
17. E.Devyatko, A.Zuckermann, M.Ruzicka, et al. Pre-emptive treatment with oral valganciclovir in management of CMV infection after cardiac transplantation. J Heart Lung Transplant. 2004;23:1277–1282.
18. C.Paya, A.Humar, E.Dominguez, et al. Efficacy and safety of valganciclovir vs. Oral Ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant. 2004;4:611–620.
19. A.Asberg, A.Humar, H.Rollag, et al. Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant. 2007;7:2106–2113.
20. J.P.Gagermeier, J.D.Rusinak, N.S.Lurain, et al. Subtherapeutic ganciclovir (GCV) levels and GCV-resistant cytomegalovirus in lung transplant recipients. Transpl Infect Dis. 2014;16:941–950.• Very interesting study analyzing the relationship between valganciclovir blood concentrations with CMV kinetics in lung transplant recipients.
21. V.C.Emery, P.D.Griffiths. Prediction of cytomegalovirus load and resistance patterns after antiviral chemotherapy. Proc Natl Acad Sci USA. 2000;97:8039–8044.
22. J.K.McGavin, K.L.Goa. Ganciclovir: an update of its use in the prevention of cytomegalovirus infection and disease in transplant recipients. Drugs. 2001;61:1153–1183.
23. A.K.Le Page, M.M.Jager, C.N.Kotton, et al. International survey of cytomegalovirus management in solid organ transplantation after the publication of consensus guidelines. Transplantation. 2013;95:1455–1460.
24. A.Humar, Y.Lebranchu, F.Vincenti, et al. The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients. Am J Transplant. 2010;10:1228–1237.
25. Palmer SM, Limaye AP, Banks M, et al. Extended valganciclovir prophylaxis to prevent cytomegalovirus after lung transplantation: a randomized, controlled trial. Ann Intern Med. 2010;152:761–769.
26. H.Y.Sun, M.M.Wagener, N.Singh. Prevention of posttransplant cytomegalovirus disease and related outcomes with valganciclovir: a systematic review. Am J Transplant. 2008;8:2111–2118.
27. A.C.Kalil, A.G.Freifeld, E.R.Lyden, et al. Valganciclovir for cytomegalovirus prevention in solid organ transplant patients: an evidence-based reassessment of safety and efficacy. PLoS One. 2009;4:e5512.
28. A.C.Kalil, C.Mindru, D.F.Florescu. Effectiveness of valganciclovir 900 mg versus 450 mg for cytomegalovirus prophylaxis in transplantation: direct and indirect treatment comparison meta-analysis. Clin Infect Dis. 2011;52:313–321.
29. R.K.Avery. Low-dose valganciclovir for cytomegalovirus prophylaxis in organ transplantation: is less really more? Clin Infect Dis. 2011;52:322–324.
30. H.G.Prentice. Use of acyclovir for prophylaxis of herpes infections in severely immunocompromised patients. J Antimicrob Chemother. 1983;12 (Suppl B):153–159.
31. J.D.Meyers, J.C.Wade, R.W.McGuffin, et al. The use of acyclovir for cytomegalovirus infections in the immunocompromised host. J Antimicrob Chemother. 1983;12(Suppl B):181–193.
32. D.Lowance, H.H.Neumayer, C.M.Legendre, et al. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group. N Engl J Med 1999;340:1462–1470.
33. S.M.Flechner, R.K.Avery, R.Fisher, et al. A randomized prospective controlled trial of oral acyclovir versus oral ganciclovir for cytomegalovirus prophylaxis in high-risk kidney transplant recipients. Transplantation. 1998;66:1682–1688.
34. S.R.Duncan, W.F.Grgurich, A.T.Iacono, et al. A comparison of ganciclovir and acyclovir to prevent cytomegalovirus after lung transplantation. Am J Respir Crit Care Med. 1994;150:146–152.
35. D.M.Zuk, A.Humar, J.G.Weinkauf, et al. An international survey of cytomegalovirus management practices in lung transplantation. Transplantation. 2010;90:672–676.
36. T.Reischig, P.Jindra, O.Hes, et al. Valacyclovir prophylaxis versus preemptive valganciclovir therapy to prevent cytomegalovirus disease after renal transplantation. Am J Transplant. 2008;8:69–77.
37. T.Reischig, M.Kacer, P.Jindra, et al. Randomized trial of valganciclovir versus valacyclovir prophylaxis for prevention of cytomegalovirus in renal transplantation. Clin J Am Soc Nephrol: CJASN. 2015;10:294–304.
38. L.Kielberger, M.Bouda, P.Jindra, et al. Pharmacoeconomic impact of different regimens to prevent cytomegalovirus infection in renal transplant recipients. Kidney Blood Press Res. 2012;35:407–416.
39. T.Reischig, P.Hribova, P.Jindra, et al. Long-term outcomes of pre-emptive valganciclovir compared with valacyclovir prophylaxis for prevention of cytomegalovirus in renal transplantation. J Am Soc Nephrol. 2012;23:1588–1597.
40. L.R.Minces, M.H.Nguyen, D.Mitsani, et al. Ganciclovir-resistant cytomegalovirus infections among lung transplant recipients are associated with poor outcomes despite treatment with foscarnet-containing regimens. Antimicrob Agents Chemother. 2014;58:128–135.• This study highlights the poor clinical outcomes of lung transplant recipients developing ganciclovir resistance, despite foscarnet treatment is effective in clearing off the infection.
41. A.P.Limaye, L.Corey, D.M.Koelle, et al. Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants. Lancet. 2000;356:645–649.
42. A.P.Limaye, G.Raghu, D.M.Koelle, et al. High incidence of ganciclovir-resistant cytomegalovirus infection among lung transplant recipients receiving preemptive therapy. J Infect Dis. 2002;185:20–27.
43. V.Tischler, M.M.Schuurmans, A.Boehler, et al. Crystal precipitation and granulomatous inflammation in multiple organs after foscarnet therapy in a lung transplant recipient. J Heart Lung Transplant. 2012;31:1037–1040.
44. A.J.Eid, S.K.Arthurs, P.J.Deziel, et al. Emergence of drug-resistant cytomegalovirus in the era of valganciclovir prophylaxis: therapeutic implications and outcomes. Clin Transplant. 2008;22:162–170.
45. Combination foscarnet and ganciclovir therapy vs monotherapy for the treatment of relapsed cytomegalovirus retinitis in patients with AIDS. The cytomegalovirus retreatment trial. the studies of ocular complications of AIDS research group in collaboration with the AIDS clinical trials group. Arch Ophthalmol. 1996;114:23–33.
46. I.Gracia-Ahufinger, J.Gutierrez-Aroca, E.Cordero, et al. Use of high-dose ganciclovir for the treatment of cytomegalovirus replication in solid organ transplant patients with ganciclovir resistance-inducing mutations. Transplantation. 2013;95:1015–1020.
47. G.Andrei, D.Topalis, T.De Schutter, et al. Insights into the mechanism of action of cidofovir and other acyclic nucleoside phosphonates against polyoma- and papillomaviruses and non-viral induced neoplasia. Antiviral Res. 2015;114:21–46.
48. P.Griffiths, S.Lumley. Cytomegalovirus. Curr Opin Infect Dis. 2014;27:554–559.
49. D.J.Winston, F.Saliba, E.Blumberg, et al. Efficacy and safety of maribavir dosed at 100 mg orally twice daily for the prevention of cytomegalovirus disease in liver transplant recipients: a randomized, double-blind, multicenter controlled trial. Am J Transplant. 2012;12:3021–3030.
50. F.M.Marty, D.J.Winston, S.D.Rowley, et al. CMX001 to prevent cytomegalovirus disease in hematopoietic-cell transplantation. N Engl J Med. 2013;369:1227–1236.
51. R.F.Chemaly, A.J.Ullmann, S.Stoelben, et al. Letermovir for cytomegalovirus prophylaxis in hematopoietic-cell transplantation. N Engl J Med. 2014;370:1781–1789.
52. S.Roy, R.Arav-Boger. New cell-signaling pathways for controlling cytomegalovirus replication. Am J Transplant. 2014;14:1249–1258.• Recommended review article providing an overview on potential novel therapeutic targets for CMV infection.
53. C.V.Paya. Indirect effects of CMV in the solid organ transplant patient. Transpl Infect Dis. 1999;1(Suppl 1):8–12.
54. P.Grossi, P.Mohacsi, Z.Szabolcs, et al. Cytomegalovirus immunoglobulin after thoracic transplantation: an overview. Transplantation. 2016;100:s1–s3.
55. M.Radosevich, T.Burnouf. Intravenous immunoglobulin G: trends in production methods, quality control and quality assurance. Vox Sang. 2010;98:12–28.
56. J.Carbone. The immunology of posttransplant CMV infection: potential effect of CMV immunoglobulins on distinct components of the immune response to CMV. Transplantation. 2016;100:S11–S8.
57. E.Sarmiento, N.Lanio, A.Gallego, et al. Immune monitoring of anti cytomegalovirus antibodies and risk of cytomegalovirus disease in heart transplantation. Int Immunopharmacol. 2009;9:649–652.
58. M.H.Yamani, R.Avery, S.D.Mawhorter, et al. The impact of CytoGam on cardiac transplant recipients with moderate hypogammaglobulinemia: a randomized single-center study. J Heart Lung Transplant. 2005;24:1766–1769.
59. N.E.Bonaros, A.Kocher, D.Dunkler, et al. Comparison of combined prophylaxis of cytomegalovirus hyperimmune globulin plus ganciclovir versus cytomegalovirus hyperimmune globulin alone in high-risk heart transplant recipients. Transplantation. 2004;77:890–897.
60. R.M.Kruger, S.Paranjothi, G.A.Storch, et al. Impact of prophylaxis with cytogam alone on the incidence of CMV viremia in CMV-seropositive lung transplant recipients. J Heart Lung Transplant. 2003;22:754–763.
61. H.J.Metselaar, A.H.Balk, B.Mochtar, et al. Cytomegalovirus seronegative heart transplant recipients. Prophylactic Use of Anti-Cmv Immunoglobulin. Chest. 1990;97:396–399.
62. A.H.Balk, W.Weimar, P.H.Rothbarth, et al. Passive immunization against cytomegalovirus in allograft recipients. The Rotterdam Heart Transplant Program experience. Infection 1993;21:195–200.
63. L.Potena, C.T.Holweg, C.Chin, et al. Acute rejection and cardiac allograft vascular disease is reduced by suppression of subclinical cytomegalovirus infection. Transplantation. 2006;82:398–405.
64. P.Solidoro, L.Delsedime, C.Costa, et al. Effect of CMV-immunoglobulins (cytotect biotest) prophylaxis on CMV pneumonia after lung transplantation. New Microbiol. 2011;34:33–36.
65. P.Solidoro, D.Libertucci, L.Delsedime, et al. Combined cytomegalovirus prophylaxis in lung transplantation: effects on acute rejection, lymphocytic bronchitis/bronchiolitis, and herpesvirus infections. Transplant Proc. 2008;40:2013–2014.
66. E.Ruttmann, C.Geltner, B.Bucher, et al. Combined CMV prophylaxis improves outcome and reduces the risk for bronchiolitis obliterans syndrome (BOS) after lung transplantation. Transplantation. 2006;81:1415–1420.
67. D.Weill, B.J.Lock, D.L.Wewers, et al. Combination prophylaxis with ganciclovir and cytomegalovirus (CMV) immune globulin after lung transplantation: effective CMV prevention following daclizumab induction. Am J Transplant. 2003;3:492–496.
68. J.Carbone, E.Sarmiento, J.Palomo, et al. The potential impact of substitutive therapy with intravenous immunoglobulin on the outcome of heart transplant recipients with infections. Transplant Proc. 2007;39:2385–2388.
69. S.C.Jordan, M.Toyoda, A.A.Vo. Intravenous immunoglobulin a natural regulator of immunity and inflammation. Transplantation. 2009;88:1–6.
70. U.Shulz, P.Solidoro, V.Muller, et al. CMV immunoglobulins for the treatment of cmv infections in thoracic transplant recipients. Transplantation. 2016;100:S5–S10.
71. A.Asberg, A.G.Jardine, A.A.Bignamini, et al. Effects of the intensity of immunosuppressive therapy on outcome of treatment for CMV disease in organ transplant recipients. Am J Transplant. 2010;10:1881–1888.
72. Hill JA, Hummel M, Starling RC, et al. A lower incidence of cytomegalovirus infection in de novo heart transplant recipients randomized to everolimus. Transplantation. 2007;84:1436–1442.
73. L.Potena, C.D’Agostino, D.Abate, et al. Interaction of CMV prophylaxis and pre-emptive strategies with immunosuppressive therapy: potential antiviral effect of everolimus. J Heart Lung Transplant. 2010;29:S155–S6.
74. Eisen HJ, Kobashigawa J, Starling RC, et al. Everolimus versus mycophenolate mofetil in heart transplantation: a randomized, multicenter trial. Am J Transplant. 2013;13:1203–1216.
75. J.Kobashigawa, H.Ross, C.Bara, et al. Everolimus is associated with a reduced incidence of cytomegalovirus infection following de novo cardiac transplantation. Transpl Infect Dis. 2013;15:150–162.
76. B.Nashan, R.Gaston, V.Emery, et al. Review of cytomegalovirus infection findings with mammalian target of rapamycin inhibitor-based immunosuppressive therapy in de novo renal transplant recipients. Transplantation. 2012;93:1075–1085.
77. D.C.Brennan, J.M.Aguado, L.Potena, et al. Effect of maintenance immunosuppressive drugs on virus pathobiology: evidence and potential mechanisms. Rev Med Virol. 2013;23:97–125.
78. L.Demopoulos, M.Polinsky, G.Steele, et al. Reduced risk of cytomegalovirus infection in solid organ transplant recipients treated with sirolimus: a pooled analysis of clinical trials. Transplant Proc. 2008;40:1407–1410.
79. A.J.Clippinger, T.G.Maguire, J.C.Alwine. The changing role of mTOR kinase in the maintenance of protein synthesis during human cytomegalovirus infection. J Virol. 2011;85:3930–3939.
80. Q.Li, R.R.Rao, K.Araki, et al. A central role for mTOR kinase in homeostatic proliferation induced CD8+ T cell memory and tumor immunity. Immunity. 2011;34:541–553.
81. K.Araki, B.Youngblood, R.Ahmed. The role of mTOR in memory CD8 T-cell differentiation. Immunol Rev. 2010;235:234–243.
82. M.Poglitsch, T.Weichhart, M.Hecking, et al. CMV late phase-induced mTOR activation is essential for efficient virus replication in polarized human macrophages. Am J Transplant. 2012;12:1458–1468.
83. A.De Pablo, F.Santos, A.Sole, et al. Recommendations on the use of everolimus in lung transplantation. Transplant Rev (Orlando). 2013;27:9–16.
84. M.Ritta, C.Costa, P.Solidoro, et al. Everolimus-based immunosuppressive regimens in lung transplant recipients: impact on CMV infection. Antiviral Res. 2015;113:19–26.
85. A.R.Glanville, C.Aboyoun, W.Klepetko, et al. Three-year results of an investigator-driven multicenter, international, randomized open-label de novo trial to prevent BOS after lung transplantation. J Heart Lung Transplant. 2015;34:16–25.
86. S.Kuppahally, A.Al-Khaldi, D.Weisshaar, et al. Wound healing complications with de novo sirolimus versus mycophenolate mofetil-based regimen in cardiac transplant recipients. Am J Transplant. 2006;6:986–992.
87. J.K.Preiksaitis, D.C.Brennan, J.Fishman, et al. Canadian society of transplantation consensus workshop on cytomegalovirus management in solid organ transplantation final report. Am J Transplant. 2005;5:218–227.
88. N.Singh. Antiviral drugs for cytomegalovirus in transplant recipients: advantages of preemptive therapy. Rev Med Virol. 2006;16:281–287.
89. V.C.Emery. Prophylaxis for CMV should not now replace pre-emptive therapy in solid organ transplantation. Rev Med Virol. 2001;11:83–86.
90. D.R.Snydman. The case for cytomegalovirus prophylaxis in solid organ transplantation. Rev Med Virol. 2006;16:289–295.
91. J.A.Khoury, G.A.Storch, D.L.Bohl, et al. Prophylactic versus preemptive oral valganciclovir for the management of cytomegalovirus infection in adult renal transplant recipients. Am J Transplant. 2006;6:2134–2143.
92. L.Potena, F.Grigioni, G.Magnani, et al. Prophylaxis versus preemptive anti-cytomegalovirus approach for prevention of allograft vasculopathy in heart transplant recipients. J Heart Lung Transplant. 2009;28:461–467.
93. O.Manuel, G.Kralidis, N.J.Mueller, et al. Impact of antiviral preventive strategies on the incidence and outcomes of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant. 2013;13:2402–2410.• This study represents a snapshot of current practice for CMV prevention in the United States. The results support the concept that prophylaxis may exert a greater graft protection effect than preemptive strategy.
94. Y.A.Puius, D.R.Snydman. Prophylaxis and treatment of cytomegalovirus disease in recipients of solid organ transplants: current approach and future challenges. Curr Opin Infect Dis. 2007;20:419–424.
95. B.Perciaccante, G.Bianchi, L.Potena, et al. Everolimus and valganciclovir prophylaxis: how to chase CMV but not the patient: insights from PROTECT randomized study. J Heart Lung Transpl. 2015;34:S305.
96. C.N.Kotton, D.Kumar, A.M.Caliendo, et al. International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation. 2010;89:779–795.
97. G.Gerna, F.Baldanti, M.Torsellini, et al. Evaluation of cytomegalovirus DNAaemia versus pp65-antigenaemia cutoff for guiding preemptive therapy in transplant recipients: a randomized study. Antivir Ther. 2007;12:63–72.
98. S.K.Sanghavi, K.Abu-Elmagd, M.C.Keightley, et al. Relationship of cytomegalovirus load assessed by real-time PCR to pp65 antigenemia in organ transplant recipients. J Clin Virol. 2008;42:335–342.
99. C.Martin-Gandul, P.Perez-Romero, M.Sanchez, et al. Determination, validation and standardization of a CMV DNA cut-off value in plasma for preemptive treatment of CMV infection in solid organ transplant recipients at lower risk for CMV infection. J Clin Virol. 2013;56:13–18.
100. G.Gerna, D.Lilleri, V.Rognoni, et al. Preemptive therapy for systemic and pulmonary human cytomegalovirus infection in lung transplant recipients. Am J Transplant. 2009;9:1142–1150.
101. V.C.Emery, C.A.Sabin, A.V.Cope, et al. Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation. Lancet. 2000;355:2032–2036.
102. D.Lilleri, T.Lazzarotto, V.Ghisetti, et al. Multicenter quality control study for human cytomegalovirus DNAemia quantification. New Microbiol. 2009;32:245–253.
103. X.L.Pang, J.D.Fox, J.M.Fenton, et al. Interlaboratory comparison of cytomegalovirus viral load assays. Am J Transplant. 2009;9:258–268.
104. R.T.Hayden, J.Preiksaitis, Y.Tong, et al. Commutability of the first world health organization international standard for human cytomegalovirus. J Clin Microbiol. 2015;53:3325–3333.
105. C.C.Bauer, P.Jaksch, S.W.Aberle, et al. Relationship between cytomegalovirus DNA load in epithelial lining fluid and plasma of lung transplant recipients and analysis of coinfection with Epstein-Barr virus and human herpesvirus 6 in the lung compartment. J Clin Microbiol. 2007;45:324–328.
106. D.Lilleri, G.Gerna, F.Bruno, et al. Systemic and local human cytomegalovirus-specific T-cell response in lung transplant recipients. New Microbiol. 2013;36:267–277.• This study provides evidences that immune response against CMV may be exerted locally in the lung allograft, and not be detected in the bloodstream. The local response appears to be more protective than the systemic one.
107. C.Costa, A.Curtoni, F.Sidoti, et al. Detection of human cytomegalovirus in transbronchial biopsies from lung transplant recipients. Arch Virol. 2013;158:1461–1465.
108. S.Ke, D.M.Lyu, T.J.Grazia, et al. Late-onset cytomegalovirus (CMV) in lung transplant recipients: can CMV serostatus guide the duration of prophylaxis? Am J Transplant. 2013;13:376–382.• Very large observational study supporting that in lung transplantation donor serology represents a risk factor for CMV disease also in seropositive recipients.
109. C.Costa, A.Saldan, F.Sinesi, et al. The lack of cytomegalovirus-specific cellular immune response may contribute to the onset of organ infection and disease in lung transplant recipients. Int J Immunopathol Pharmacol. 2012;25:1003–1009.• This study supports the use of elispot to identify lung recipients at highest risk for CMV disease.
110. Lazzarotto T, Varani S, Spezzacatena P, et al. Delayed acquisition of high-avidity anti-cytomegalovirus antibody is correlated with prolonged antigenemia in solid organ transplant recipients. J Infect Dis. 1998;178:1145–1149.
111. W.Tu, L.Potena, P.Stepick-Biek, et al. T-cell immunity to subclinical cytomegalovirus infection reduces cardiac allograft disease. Circulation. 2006;114:1608–1615.
112. A.Egli, M.SilvaJr., D.O’Shea, et al. An analysis of regulatory T-cell and Th-17 cell dynamics during cytomegalovirus replication in solid organ transplant recipients. PLoS One. 2012;7:e43937.
113. G.P.Westall, N.A.Mifsud, T.Kotsimbos. Linking CMV serostatus to episodes of CMV reactivation following lung transplantation by measuring CMV-specific CD8+ T-cell immunity. Am J Transplant. 2008;8:1749–1754.
114. O.Manuel, S.Husain, D.Kumar, et al. Assessment of cytomegalovirus-specific cell-mediated immunity for the prediction of cytomegalovirus disease in high-risk solid-organ transplant recipients: a multicenter cohort study. Clin Infect Dis. 2013;56:817–824.
115. L.F.Lisboa, D.Kumar, L.E.Wilson, et al. Clinical utility of cytomegalovirus cell-mediated immunity in transplant recipients with cytomegalovirus viremia. Transplantation. 2012;93:195–200.
116. G.P.Westall, Y.Cristiano, A.Y.Peleg, et al. Interim analysis: a study of quantiFERON-CMV-Directed CMV prophylaxis versus standard-of-care to reduce late cmv reactivation in patients undergoing lung transplantation. J Heart Lung Transplant. 2016;35:S105.
117. P.Solidoro, C.Costa, D.Libertucci, et al. Tailored cytomegalovirus management in lung transplant recipient: a single-center experience. Transplant Proc. 2013;45:2736–2740.
118. P.Griffiths, S.Plotkin, E.Mocarski, et al. Desirability and feasibility of a vaccine against cytomegalovirus. Vaccine. 2013;31(Suppl 2):B197–B203.
119. P.D.Griffiths, A.Stanton, E.McCarrell, et al. Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial. Lancet. 2011;377:1256–1263.